Home Page Settlements Fibrinogen Hepatitis
Fibrinogen HepatitisTokyo, Japan: (Nov-01-07) Five lawsuits were brought against Mitsubishi Tanabe Pharma Corp., a Japanese pharmaceutical company, alleging that customers who used Fibrinogen, which is used to stop bleeding, ended up victims of hepatitis virus-tainted blood products. Mitsubishi Tanabe, a newly merged firm that incorporates the producer of the medical product under state license, said it had agreed to reach a settlement in five lawsuits filed over the disease.
As part of the settlement agreement, the company agreed to pay 2.1 billion yen ($18.17 million) to resolve the case. The government and the company estimate at least 10,000 Japanese people have been infected with potentially fatal hepatitis C after being administered with Fibrinogen. Sources stated that Fibrinogen was widely used at Japanese hospitals until 1988, mostly during surgeries or after women gave birth, even though the US government had warned the public of its danger in 1977. The company is being targeted for its failure to respond to requests by victims for information disclosure and to swiftly notify people who might have contracted the disease. [
Legal HelpIf you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.
Last updated on Nov-3-07
READ MORE [ Drugs/Medical Settlements and Legal News ]